• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Helius Medical Technologies Inc.

    7/10/25 4:16:55 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HSDT alert in real time by email
    S-8 1 tm2520226d1_s8.htm S-8

     

    As filed with the Securities and Exchange Commission on July 10, 2025

    Registration No. 333-

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

     

    HELIUS MEDICAL TECHNOLOGIES, INC.
    (Exact name of registrant as specified in its charter)

     

     

    Delaware   36-4787690

    (State or other jurisdiction of
    incorporation or organization)

      (I.R.S. Employer
    Identification No.)
       

    642 Newtown Yardley Road, Suite 100
    Newtown, Pennsylvania

      18940
    (Address of principal executive offices)   (Zip code)

     

    Helius Medical Technologies, Inc. 2022 Equity Incentive Plan

    (Full title of the plan)

     

    Dane C. Andreeff
    President and Chief Executive Officer
    Helius Medical Technologies, Inc.
    642 Newtown Yardley Road, Suite 100
    Newtown, Pennsylvania 18940
    (215) 944-6100
    (Name, address, and telephone number, including area code, of agent for service)

     

     

    Copy to:

     

    Phillip D. Torrence, Esq.
    Jeffrey Kuras, Esq.
    Honigman LLP
    650 Trade Center Way, Suite 200
    Kalamazoo, Michigan 49002-0402
    (269) 337-7700

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     Large accelerated filer   ¨   Accelerated filer   ¨
           
    Non-accelerated filer   x   Smaller reporting company   x
           
            Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    2022 Equity Incentive Plan

     

    This Registration Statement on Form S-8 is being filed by Helius Medical Technologies, Inc. (the “Company,” the “Registrant,” “we,” “us,” or “our”), for the purpose of registering an additional 240,000 shares of Class A common stock, par value $0.001 per share (the “Common Stock”), that may be issued pursuant to Awards (as defined in the 2022 Equity Incentive Plan) under the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan, as amended (the “2022 Equity Incentive Plan”).

     

    Pursuant to General Instruction E to Form S-8, this Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the Company on Form S-8 relating to the 2022 Equity Incentive Plan, respectively, are effective, and the Company’s Registration Statements on Form S-8 previously filed with the Securities and Exchange Commission (the “Commission”) on May 31, 2022 (File No. 333-265324), January 19, 2023 (File No. 333-269305), July 24, 2024 (File No. 333-280978) and March 25, 2025 (File No. 333-286100) registering shares of Common Stock issuable under the 2022 Equity Incentive Plan are incorporated by reference and made part of this Registration Statement, except as amended hereby.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed with the Securities and Exchange Commission (the “Commission”) by the Registrant are hereby incorporated by reference in this Registration Statement:

     

    a)the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Commission on March 25, 2025;

     

    b)the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the Commission on May 1, 2025;

     

    c)the Registrant’s Current Reports on Form 8-K filed with the Commission on January 15, 2025, January 24, 2025, February 7, 2025, April 4, 2025, April 22, 2025, April 25, 2025, April 30, 2025, May 23, 2025, June 4, 2025, June 20, 2025, June 23, 2025, June 27, 2025, July 7, 2025 and July 9, 2025 and

     

    d)the description of the Registrant’s Common Stock contained in the Registrant’s Form 8-A (File No. 001-38445) filed with the Commission on April 4, 2018, as amended by the description of the Common Stock contained in Exhibit 4.7 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020, and as further amended by any subsequent amendment or report filed for the purpose of updating such description.

     

    In addition, all documents the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), after the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities covered hereby then remaining unsold are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents. Notwithstanding anything herein, the Registrant is not incorporating by reference any information furnished under Item 2.02 or Item 7.01 of any Current Report on Form 8-K, unless, and to the extent, specified in any such Current Report on Form 8-K.

     

    Any statement herein or contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any subsequently filed document, which also is or is deemed to be incorporated by reference herein, modifies or supersedes such prior statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    We are incorporated under the laws of the State of Delaware. Section 102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, except where the director or officer breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit.

     

     

     

    Section 145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines upon application that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

     

    As permitted by the Delaware General Corporation Law, our amended and restated bylaws provide that: (1) we are required to indemnify our directors and executive officers to the fullest extent permitted by the Delaware General Corporation Law; (2) we may, in our discretion, indemnify our other officers, employees and agents as set forth in the Delaware General Corporation Law; (3) we are required, upon satisfaction of certain conditions, to advance all expenses incurred by our directors and executive officers in connection with certain legal proceedings; (4) the rights conferred in the bylaws are not exclusive; (5) we are authorized to enter into indemnification agreements with our directors, officers, employees and agents; and (6) we may secure insurance on behalf of any director, officer, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law.

     

    Indemnification Agreements

     

    We have entered into indemnification agreements with our directors and officers. These agreements provide broader indemnity rights than those provided under the Delaware General Corporation Law and the Registrant’s certificate of incorporation, as amended. The indemnification agreements are not intended to deny or otherwise limit third-party or derivative suits against us or our directors or officers, but to the extent a director or officer were entitled to indemnity or contribution under the indemnification agreement, the financial burden of a third-party suit would be borne by us, and we would not benefit from derivative recoveries against the director or officer. Such recoveries would accrue to our benefit but would be offset by our obligations to the director or officer under the indemnification agreement.

     

    Insurance Policy

     

    We maintain a directors’ and officers’ liability insurance policy. The policy insures directors and officers against unindemnified losses arising from certain wrongful acts in their capacities as directors and officers and reimburses us for those losses for which we have lawfully indemnified the directors and officers. The policy contains various exclusions.

     

    The foregoing summaries are not intended to be exhaustive and are qualified in their entirety by reference to the complete text of the statute, the Registrant’s certificate of incorporation, as amended and the agreements referred to above and are qualified in their entirety by reference thereto.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

     

     

    Item 8. Exhibits.

     

    EXHIBIT INDEX

     

    The following exhibits are filed as part of this registration statement.

     

    INDEX TO EXHIBITS

     

    Exhibit
    Number
      Description
         
    4.1   Certificate of Conversion filed with the Delaware Secretary of State on July 18, 2018 (incorporated by reference to Exhibit 3.1 to the Form 10-Q filed August 9, 2018)
         
    4.2   Certificate of Incorporation, as corrected (incorporated by reference to Exhibit 3.1 to the Form 8-K filed October 30, 2018)
         
    4.3   Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on December 31, 2020)
         
    4.4   Certificate of Designation of the Series B Preferred Stock of the Registrant (incorporated by reference to Exhibit 3.1(a) to the Registration Statement on Form 8-A, filed March 24, 2023)
         
    4.5   Corrected Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Form 8-K filed August 16, 2023)
         
    4.6   Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Form 8-K filed April 30, 2025)
         
    4.7   Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Form 8-K filed March 15, 2024)
         
    4.8   Helius Medical Technologies, Inc. 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K filed February 18, 2022)
         
    4.9   Helius Medical Technologies, Inc. 2022 Equity Incentive Plan Form of Stock Option Agreement (incorporated by reference to Exhibit 10.3 to the Form 8-K filed February 18, 2022)
         
    4.10   Amendment to the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K filed June 28, 2024)
         
    4.11*   Second Amendment to the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan
         
    5.1*   Opinion of Honigman LLP
         
    23.1*   Consent of Baker Tilly US, LLP
         
    23.2*   Consent of Honigman LLP (included in its opinion filed as Exhibit 5.1 to this Registration Statement)
         
    24.1*   Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement)
         
    107*   Filing Fee Table

     

    *Filed herewith.

     

     

     

    Item 9. Undertakings.

     

    (a) The Registrant hereby undertakes:

     

      (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

      (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
         
      (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective Registration Statement;
         
      (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

      provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Registration Statement; and

     

      (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
         
      (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, hereunto duly authorized, in the City of Newtown, State of Pennsylvania, on July 10, 2025.

     

      Helius Medical Technologies, Inc.
       
      By: /s/ Dane C. Andreeff
        Name: Dane C. Andreeff
        Title: President and Chief Executive Officer

     

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dane C. Andreeff and Jeffrey S. Mathiesen as his or her true and lawful attorneys-in-fact and agents with full power of substitution, severally, for him in any and all capacities, to sign the Registration Statement on Form S-8 of Helius Medical Technologies, Inc., and any or all amendments (including post-effective amendments thereto), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature   Title   Date
             
    /s/ Dane C. Andreeff   President, Chief Executive Officer   July 10, 2025
    Dane C. Andreeff   (Principal Executive Officer) and Director    
             
    /s/ Jeffrey S. Mathiesen   Chief Financial Officer   July 10, 2025
    Jeffrey S. Mathiesen   (Principal Financial Officer and Principal Accounting Officer),
    Treasurer, Secretary and Director
       
             
    /s/ Paul Buckman   Director   July 10, 2025
    Paul Buckman        
             
    /s/ Blane Walter   Director   July 10, 2025
    Blane Walter        
             
    /s/ Sherrie Perkins   Director   July 10, 2025
    Sherrie Perkins        
             
    /s/ Edward M. Straw   Director   July 10, 2025
    Edward M. Straw        

     

     

     

    Get the next $HSDT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HSDT

    DatePrice TargetRatingAnalyst
    11/15/2021Outperform → Market Perform
    Noble Capital Markets
    More analyst ratings

    $HSDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CFO and Treasurer Mathiesen Jeffrey S

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      7/3/25 8:00:26 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Favit-Van Pelt Antonella R.

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      7/3/25 8:00:28 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Walter Blane

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      7/3/25 8:00:24 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation

      NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under the current Breakthrough Device Designation. The key primary outcomes from the SRP indicate that: A double-blind randomized clinical trial met the primary endpoint of demonstrating statistically significant greater impr

      7/21/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. Compliant with Nasdaq's Continued Listing Requirements

      NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on July 7, 2025, Helius received formal notice from the Nasdaq Hearings Panel of the Nasdaq Stock Market LLC (the "Panel") indicating that Helius has evidenced compliance with the equity requirement in Listing Rule 5550(b)(1) (the "Equity Rule") for continued listing on the Nasdaq Capital Market. As previously disclosed, on June 3, 2025, the Company received formal notification from Nasdaq confirming that the Company had regain

      7/9/25 8:30:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies Announces Reverse Stock Split

      NEWTOWN, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-50 reverse split of its Class A common stock, par value $0.001 ("common stock"), effective at 5:00 pm Eastern time on June 30, 2025. Beginning on July 1, 2025, the Company's common stock will trade on The Nasdaq Capital Market on a split adjusted basis. At the Company's special meeting of stockholders on May 23, 2025, the stockholders approved a proposal to amend the Company's Certificate of Incorporation to effect a reverse s

      6/27/25 8:30:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    SEC Filings

    See more
    • Helius Medical Technologies Inc. filed SEC Form 8-K: Other Events

      8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      7/21/25 7:05:18 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 filed by Helius Medical Technologies Inc.

      S-8 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      7/10/25 4:16:55 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies Inc. filed SEC Form 8-K: Other Events

      8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

      7/9/25 9:00:12 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)

      4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      2/15/24 4:06:00 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      12/15/23 7:00:42 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)

      4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

      12/4/23 8:30:12 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Helius Medical Tech downgraded by Noble Capital Markets

      Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform

      11/15/21 10:55:44 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Noble Capital Markets initiated coverage on Helius Medical with a new price target

      Noble Capital Markets initiated coverage of Helius Medical with a rating of Outperform and set a new price target of $20.00

      3/24/21 8:02:45 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LADENBURG THALM/SH SH initiated coverage on Helius Medical Technologies

      LADENBURG THALM/SH SH initiated coverage of Helius Medical Technologies with a rating of Buy

      2/12/21 8:21:57 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Leadership Updates

    Live Leadership Updates

    See more
    • Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

      -Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major

      6/11/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting

      NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results of a new study confirming the therapeutic regimen and sustained efficacy of its Portable Neuromodulation Stimulator (PoNS®) device for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The event runs from May 28-31 at the Phoenix Convention Center in Phoenix. Deborah Backus, PT, Ph.D., FACRM – Vice President of Research and Innovation at Atlanta's Shepherd Center, one of six sit

      5/20/25 7:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. Appoints Paul Buckman to its Board of Directors

      NEWTOWN, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the appointment of Paul Buckman to its Board of Directors, effective September 10, 2021. Mr. Buckman will serve as Chair of the Company's Audit Committee and as a member of its Compensation and Nominating & Governance Committees. "Paul is a highly accomplished executive with more than 30 years of experience in the medical device sector, including senior leadership positions at some of the most well-regarded companies in the industry," said Blane Walter, Chairman of Helius' Board of Directors. "I

      9/14/21 7:05:00 AM ET
      $HSDT
      $LIVN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Financials

    Live finance-specific insights

    See more
    • Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

      NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today provided updates on its efforts to achieve fair market access for its Portable Neuromodulation Stimulator (PoNS) device and announced plans to host a business update call today at 9:00am ET.   "We disagree with the proposed pricing for the PoNS Mouthpiece and are disappointed CMS has once again mapped the Controller pricing to a code for fundamentally different technology," said Dane Andreeff, Helius' President and Chief Executive Officer. "I

      11/18/24 8:01:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024

      NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date:Monday, Augus

      8/6/24 4:36:06 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024

      NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2024 financial results on Monday, May 13, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date: Monday, May 13, 2

      5/10/24 9:00:00 AM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HSDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

      SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

      11/8/24 5:12:24 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Helius Medical Technologies Inc.

      SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

      5/14/24 4:15:39 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Helius Medical Technologies Inc. (Amendment)

      SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

      2/13/24 7:09:07 PM ET
      $HSDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care